01521 FRONTAGE
- 1.260
- -0.010-0.79%
FRONTAGE News
Hong Kong Stock Afternoon Review | The three major indices of Hong Kong stocks pulled back, and the Tech Index fell nearly 2%; PV stocks reversed the market, and GCL Technology rose more than 6%
Technology Network stocks declined; Bilibili fell more than 6%, NetEase fell more than 4%, Kuaishou and Meituan fell nearly 4%; as concept stocks declined, Huazhu Group fell more than 3%, and Jiumaojiu fell nearly 3%.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Intraday Overview | The three major indices of Hong Kong stocks weakened slightly, and the pharmaceutical outsourcing concept rose against the market
Road transport stocks strengthened; Guangzhou-Shenzhen Railway shares rose more than 9%, Anhui Wantong Expressway rose more than 6%; domestic housing stocks collectively pulled back, Agile Group fell more than 6%, and Midea Real Estate fell more than 5%.
Fangda Holdings (01521.HK)'s revenue for the first quarter was about 63.9 million US dollars, up 8.3% year-on-year
Gelonghui, April 25 | Fangda Holdings (01521.HK) announced that for the three months ended March 31, 2024, the Group recorded a net loss of about 1.0 million US dollars, while the net loss was about 0.9 million US dollars for the same period in 2023; revenue was about 63.9 million US dollars, an increase of 8.3% over the same period of about 59.0 million US dollars in the same period in 2023. After deducting share-based compensation expenses, amortization of intangible assets from mergers and acquisitions, and merger-related expenses, the Group's adjusted net profit was approximately US$2.2 million, an increase of 15.8% over the same period in 2023 of approximately US$1.9 million.
方達控股：2023年度報告
Haitong International: Maintaining Fangda Holdings (01521)'s “superior to market” rating target price reduction of 44% to HK$1.89
The Zhitong Finance App learned that Haitong International released a research report stating that maintaining the “superior to market” rating of Fangda Holdings (01521) was affected by the decline in global biomedical investment and financing growth, adjusted the company's 2024-2026 revenue to US$3,360, and 422 million, respectively; the adjusted net profit was US$0.34, 0.43, and US$52 million, with year-on-year growth rates of 40%, 28%, and 20%, respectively, cutting the target price from HK$3.4 to HK$1.89. In North America, the company acquired Nuro in Toronto, Canada
Fangda Holdings (01521.HK): Short-term fluctuations in performance are optimistic about the company's long-term steady development
The company announced 2023 results: In 2023, operating income was $259.9 million (+3.8%), gross margin was 30.2% (-5.4pp), and net profit was $10.7 million (-58.7%)
Fangda Holdings (01521.HK) cancelled 63.1 million shares on April 15
Gelonghui, April 15, 丨 Fangda Holdings (01521.HK) announced that on April 15, 2024, the company cancelled 63.1 million repurchased shares.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Fangda Holdings (1521.HK) Updated Report: 2023 performance falls short of expectations and still faces challenges in the short term
The 2023 results fell short of expectations. The company's revenue in 2023 increased 3.8% year over year to US$260 million, gross profit fell 12.1% year over year to US$78.39 million, and shareholders' net profit fell sharply by 58.0% year on year to 1,
Frontage Holdings' Net Profit Plunges 59% in 2023
Frontage Holdings' (HKG:1521) net profit slumped 58.7% to $10.7 million in 2023 from $25.9 million in the previous year. Basic earnings per share declined to $0.0053 from $0.0126 a year ago, according
Fangda Holdings (01521) announced annual results. After adjustment, net profit of 24 million US dollars decreased by 33.7% year on year
Fangda Holdings (01521) announced the results for the year ended December 31, 2023. The group obtained 2 profits...
FRONTAGE: ANNOUNCEMENT ON ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2023
EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials in the United States to Improve "Drug Lag" and "Drug Loss" Issues in Japan
EXTON, Pa., March 26, 2024 /PRNewswire/ -- EPNextS Group, a Japanese based leading provider of clinical trial solutions, and Frontage Laboratories, Inc., a US based full-service contract research org
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
Fangda Holdings (01521.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 15, 丨 Fangda Holdings (01521.HK) announced that a board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
FRONTAGE: DATE OF BOARD MEETING
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Analysis
Price Target
No Data
